Loading
A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in colorectal cancer, now recruiting.
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06008119 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-10-25. Conditions listed: Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.
Shares Shanghai Kechow Pharma, Tunlametinib, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors, Colorectal cancer.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors, Colorectal cancer.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.